Vnitřní lékařství, 2001 (vol. 47), Supplement 1
[Positron emission tomography (PET) in patients with malignant lymphomas--indications for the method as presented in case reports].
J Slabý, O Bělohlávek, M Trněný, P Klener
Vnitr Lek 2001, 47(Supplement 1):4-7
Positron emission tomography is a modern functional imaging method recently available also in the Czech Republic. The authors try to present indications of this method in the form of case-histories of patients with malignant lymphomas.
[Prognostic significance of cytogenetic changes in patients with acute myeloid leukemia (AML). (Analysis of results in 105 patients treated at the Hemato-oncology Clinic of the University Hospital in Olomouc from 1997 to 2000].
M Jarosová, K Indrák, M Holzerová, J Hubácek, E Faber, T Papajík, L Raida, T Szotkowski, R Knotková, T Hlusí, K Jedlicková, Z Pikalová, I Sulovská
Vnitr Lek 2001, 47(Supplement 1):8-14
Chromosomal aberrations are one of the most important prognostic factors in patients with acute myeloid leukemia (AML). This work present analysis of conventional cytogenetic results completed by fluorescence in situ hybridization (FISH) obtained from 105 patients in the time of diagnosis of AML. The median age of patients was 51 years (range 19-79 years), with slight predominance of women (female to male ratio 1.2:1). The evaluated group involved all patients with AML diagnosis, treated by intensive induction chemotherapy in the Department of Hematology-oncology, University Hospital, Olomouc during last 4 years with assessable cytogenetic results....
[Collection of peripheral hematopoietic stem cells for transplantation from volunteer donors--siblings of the patients].
J Mayer, Z Korístek, M Krahulová, Z Pospísil, M Doubek, M Klabusay, Y Brychtová, V Hoffová, J Cernanská, M Krejcí, J Vorlícek
Vnitr Lek 2001, 47(Supplement 1):15-28
Peripheral stem cells obtained by stimulation of haematopoiesis by administration of so-called growth factors are used for allogenic transplantations of haematopoietic cells only since the mid-nineties of the 20th century. So far however not all potential undesirable effects of growth factor administration to healthy subjects are known. The authors present the results of a programme of allogene transplantation of peripheral blood stem cells from related donors which was started in their department in 1996. From 11/1996 till 8/2000 the authors started 55 mobilizations of peripheral stem cells in donors before transplantation. The mobilization growth...
[What is a non-myeloablative transplantation of hematopoietic cells?].
J Mayer
Vnitr Lek 2001, 47(Supplement 1):29-33
Transplantation of haematopoietic cells, dominantly peripheral stem cells, after a non-myeloablative regime is nowadays a very intensely investigated method. Its principle involves that the pretransplantation regime accentuates the immunosuppressive component to prevent transplant rejection but reduces the antitumourous component (chemotherapy or irradiation). It was demonstrated that the reaction of allogene transplanted lymphocytes against the residual tumour is the dominant anti-tumourous component of the whole allogene transplantation. Thus the acute toxicity of the whole procedure is reduced. The initial experience with this method is so far very...
[Allogenic transplantation of bone marrow in patients with chronic myeloid leukemia 1991-1995 and 1996-1998. Experience at the Hematology-Oncology Clinic of the University Hospital in Plzen].
M Karas, K Cerná, V Koza, P Jindra, V Vozobulová, M Schützová
Vnitr Lek 2001, 47(Supplement 1):34-39
The authors compare the results of allogenic bone marrow transplantations of relatives in patients with chronic myeloid leukaemia during the initial years of the transplantation programme 1991-1995 (group 1, 15 patients) with results achieved in 1996-1998 (group 2, 30 patients) and evaluate the effect of changes concerning supportive treatment and new diagnostic methods. The age median of group 1 was 35 years, the median age of group 2 46 years. In other parameters the groups were comparable. In 1991-1995 a high transplantation mortality by the 100th day was recorded (40% as compared with 17%) and a higher incidence of stage III and IV of the acute...
[Autologous transplantation of peripheral hematopoietic cells and subsequent maintenance therapy with interferon alpha or interferon alpha and dexamethasone in patients with multiple myeloma--results from the 4W randomized clinical trial of the Czech Myeloma Group].
M Krejcí, R Hájek, V Scudla, J Bacovský, K Indrák, E Faber, V Koza, M Schützová, B Kuca, E Sumná, H Franková, F Lehanka, J Gumulec, Y Stavarová, Z Rezek, P Praskac, S Cahová, M Vránová, K Veprek, J Januska, P Kessler, V Pozděnová, L Walterová, I Stefánek, P Hausdorf, I Meluzínová, L Novosadová, S Lenícková, L Dusek, A Syobodník, E Králová, Z Adam, J Mayer, J Vorlícek
Vnitr Lek 2001, 47(Supplement 1):40-47
In the clinical 4W study patients with newly diagnosed multiple myeloma are included where the state of the disease calls for treatment, while high dose chemotherapy is not contraindicated. Treatment according to protocol 4W comprises induction chemotherapy VAD, mobilization of haematopoietic cells (cyclophosphamide 5 g/m2). This is followed by autologous transplantation (as a conditioning regime melfalan 200 mg/m2 is administered). The patients are randomized into two groups, the first one is given interferon alpha as maintenance treatment, in the second group alternates cyclically interferon alpha and dexamethasone treatment. So far between 1996...
[Comparison of the effectiveness of idarubicin (Zavedos) and mitoxantrone (Refador) in induction therapy of acute myeloid leukemia in elderly patients (55-75) (a prospective multicenter randomized study conducted 1998-2000].
K Indrák, J Hubácek, J Mayer, J Voglová, M Jarosová, M Krahulová, J Malý, E Faber, M Penka, M Kmonícek, L Jebavý, T Szotkowski, R Knotková, A Hlusí, J Zapletalová
Vnitr Lek 2001, 47(Supplement 1):48-56
The presented study compares the efficacy and the toxicity of idarubicine and mitoxantrone in combination with cytosar (3 + 7) in induction treatment of the patients with AML aged 55-75. 31 patients at the age of 55-75 (median 62) were evaluated in the arm with idarubicine and 29 patients at the age of 57-74 (median 64) in the arm with mithoxantrone. Complete haematological remission was achieved in 13 patients (41.9%) in the arm with idarubicine and 15 patients (51.7%) in the arm with mitoxantrone. The medians of overall survival time (OS) and disease free survival time (DFS) were 22 and 44 weeks in the idarubicine arm and 35 and 40 weeks in the mitoxantrone...
[Non-cytostatic treatment of malignancies. Anti-CD20 monoclonal antibody (Rituximab, Mabthera) in the treatment of non-Hodgkin's lymphoma].
J Mayer, M Navrátil, J Vásová, J Vorlícek
Vnitr Lek 2001, 47(Supplement 1):57-62
Some types of non-Hodgkin lymphomas cannot be treated by contemporary preparations. After repeated relapses and chemotherapy moreover damage of bone marrow occurs and further intense cytostatic treatment is not possible. Monoclonal antibodies against structures on tumour cells are an interesting alternative of cytostatic treatment. In 2000 the authors administered anti CD20 monoclonal antibody (rituximab, Mabthera Roche), 375 mg/m2, on the 1st, 8th, 15th and 22nd day i.v. to a total of 24 patients with relapsing non-Hodgkin lymphoma. In five patients the relapse developed after high dosage chemotherapy and autologous transplantation of peripheral stem...